对比增强锥形束CT引导的原位小鼠胶质母细胞瘤分次放疗与随访监测:概念验证研究
该概念验证研究将GL261小鼠胶质母细胞瘤细胞接种至C57BL/6小鼠右半球,用对比增强锥形束CT(CBCT)监测肿瘤生长,待平均体积约7 mm3时给予每日2 Gy、累计20 Gy的分次照射。结果显示分次照射显著延缓肿瘤生长并延长生存,且重复注射对比剂耐受良好。
要点
- 对比增强CBCT可显示小鼠原位胶质母细胞瘤,检测限约2 mm3,并用于治疗计划和肿瘤体积随访。
- 每日2 Gy至累计20 Gy的分次照射显著延缓肿瘤生长并延长生存,疗效依赖束流准直设置和边缘大小。
- 重复对比剂注射耐受良好,肝酶和肌酐仅亚临床升高,肝、肾组织学形态正常。
核心结论
- 对比增强、基于CT的分次照射原位小鼠胶质母细胞瘤是可用于开发和评估多模式放疗联合新药的有力临床前技术。
研究设计与样本
- 将GL261小鼠胶质母细胞瘤细胞接种至C57BL/6小鼠右半球,用对比增强CBCT扫描监测肿瘤生长。
- 肿瘤达平均体积约7 mm3时,以每日2 Gy分次照射至累计20 Gy,采用不同束流准直设置。
- 每周两次对比增强CBCT用于治疗计划和肿瘤体积随访,通过平扫CBCT骨性结构对齐实现每日重新定位。
- 出现神经症状时以心脏灌注处死小鼠,取脑、肝、肾做组织切片,并测肝酶和肌酐血清水平评估对比剂毒性。
主要发现
- 对比增强CBCT成功显示肿瘤,检测限约2 mm3,并可进行治疗计划。
- 平扫CT骨性结构对齐用于动物每日重新定位可行。
- 分次照射显著延缓肿瘤生长,并显著延长生存,明显依赖束流准直设置和边缘大小。
- 处死当日脑切片显示肿瘤外观和体积相似。
- 重复对比剂注射耐受良好,肝酶和肌酐血清水平仅亚临床升高,肝、肾切片组织形态正常。
关键数值与推荐
- 肿瘤照射剂量为每日2 Gy分次,累计20 Gy。
- 对比增强CBCT肿瘤检测限约2 mm3。
- 肿瘤照射起始平均体积约7 mm3。
临床怎么用
- 该技术可用于临床前评估分次放疗联合新药的多模式方案,以加速临床转化。
- 对比增强CBCT可支持原位胶质母细胞瘤的治疗计划和肿瘤体积随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite aggressive treatment regimens comprising surgery and radiochemotherapy, glioblastoma (GBM) remains a cancer entity with very poor prognosis. The development of novel, combined modality approaches necessitates adequate preclinical model systems and therapy regimens that closely reflect the clinical situation. So far, image-guided, fractionated radiotherapy of orthotopic GBM models represents a major limitation in this regard. METHODS: GL261 mouse GBM cells were inoculated into the right hemispheres of C57BL/6 mice. Tumor growth was monitored by contrast-enhanced conebeam CT (CBCT) scans. When reaching an average volume of approximately 7 mm3, GBM tumors were irradiated with daily fractions of 2 Gy up to a cumulative dose of 20 Gy in different beam collimation settings. For treatment planning and tumor volume follow-up, contrast-enhanced CBCT scans were performed twice per week. Daily repositioning of animals was achieved by alignment of bony structures in native CBCT scans. When showing neurological symptoms, mice were sacrificed by cardiac perfusion. Brains, livers, and kidneys were processed into histologic sections. Potential toxic effects of contrast agent administration were assessed by measurement of liver enzyme and creatinine serum levels and by histologic examination. RESULTS: Tumors were successfully visualized by contrast-enhanced CBCT scans with a detection limit of approximately 2 mm3, and treatment planning could be performed. For daily repositioning of the animals, alignment of bony structures in native CT scans was well feasible. Fractionated irradiation caused a significant delay in tumor growth translating into significantly prolonged survival in clear dependence of the beam collimation setting and margin size. Brain sections revealed tumors of similar appearance and volume on the day of euthanasia. Importantly, the repeated contrast agent injections were well tolerated, as liver enzyme and creatinine serum levels were only subclinically elevated, and liver and kidney sections displayed normal histomorphology. CONCLUSIONS: Contrast-enhanced, CT-based, fractionated radiation of orthotopic mouse GBM represents a versatile preclinical technique for the development and evaluation of multimodal radiotherapeutic approaches in combination with novel therapeutic agents in order to accelerate translation into clinical testing.
引用
- Stegen B, Nieto A, Albrecht V, et al. Contrast-enhanced, conebeam CT-based, fractionated radiotherapy and follow-up monitoring of orthotopic mouse glioblastoma: a proof-of-concept study. Radiat Oncol. 2020. PMID: 31969174. doi:10.1186/s13014-020-1470-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。